News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
696,744 Results
Type
Article (41439)
Company Profile (292)
Press Release (655013)
Section
Business (209594)
Career Advice (2057)
Deals (36551)
Drug Delivery (88)
Drug Development (82514)
Employer Resources (170)
FDA (16362)
Job Trends (15323)
News (354178)
Policy (33778)
Tag
Academia (2572)
Africa (773)
Alliances (50913)
Alzheimer's disease (1150)
Approvals (16308)
Arizona (176)
Artificial intelligence (74)
Asia (39560)
Australia (6303)
Bankruptcy (360)
Best Places to Work (11343)
Biosimilars (64)
Biotechnology (185)
C2C Services and Suppliers (79727)
California (1532)
Canada (833)
Cancer (330)
Career advice (1719)
Cell therapy (99)
China (111)
Clinical research (64404)
Collaboration (107)
Colorado (65)
Connecticut (62)
COVID-19 (2541)
Cystic fibrosis (73)
Data (125)
Diabetes (64)
Diagnostics (6022)
Drug pricing (67)
Earnings (85285)
Employer resources (143)
Europe (83984)
Events (110134)
Executive appointments (89)
FDA (16530)
Florida (207)
Funding (93)
Gene therapy (82)
GLP-1 (525)
Government (4398)
Healthcare (18750)
Hotbed/Location (489743)
Idaho (56)
Illinois (235)
Indiana (139)
Infectious disease (2565)
Inflammatory bowel disease (90)
Interviews (316)
IPO (16439)
Job creations (4044)
Job search strategy (1481)
Kansas (93)
Layoffs (407)
Legal (8289)
Lung cancer (70)
Manufacturing (77)
Maryland (340)
Massachusetts (1307)
Medical device (13097)
Medtech (13100)
Mergers & acquisitions (19907)
Metabolic disorders (222)
Michigan (115)
Minnesota (201)
Neuroscience (1265)
New Jersey (480)
New York (480)
NextGen Class of 2024 (6601)
Non-profit (4499)
North Carolina (569)
Northern California (695)
Obesity (138)
Ohio (96)
Opinion (189)
Patents (58)
Pennsylvania (515)
People (57633)
Pharmaceutical (84)
Phase I (19865)
Phase II (28340)
Phase III (21313)
Pipeline (92)
Postmarket research (2634)
Preclinical (8472)
Press Release (68)
Rare diseases (116)
Real estate (6227)
Recruiting (65)
Regulatory (21959)
Research institute (2349)
Resumes & cover letters (354)
South America (1150)
Southern California (625)
Startups (3704)
Texas (181)
United States (7381)
Vaccines (461)
Washington State (236)
Weight loss (124)
Date
Last 7 days (471)
Last 30 days (2205)
Last 365 days (38006)
2024 (24838)
2023 (40629)
2022 (51797)
2021 (56332)
2020 (54795)
2019 (47401)
2018 (35772)
2017 (33139)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27631)
2012 (29729)
2011 (30487)
2010 (28497)
696,744 Results for "aridis pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Aridis Provides Corporate Update - June 24, 2024
Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced a corporate update on recent developments.
June 24, 2024
·
8 min read
Biotech Bay
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
Aridis Pharmaceuticals, Inc. (OTC QB: ARDS) today announced that its 2023 Annual Meeting of Stockholders (“Annual Meeting”), scheduled for Friday, December 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum.
December 15, 2023
·
6 min read
Business
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023.
November 3, 2023
·
13 min read
Deals
Aridis Pharmaceuticals Announces $2 Million Offering
Aridis Pharmaceuticals, Inc. today announced the pricing of an offering of 10,000,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share.
August 2, 2023
·
7 min read
Business
Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today reported financial and corporate results for its first quarter ended March 31, 2023.
June 8, 2023
·
14 min read
Biotech Bay
Aridis Provides Corporate Update
Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced a corporate update on recent developments.
March 31, 2023
·
7 min read
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Biotech Bay
Aridis Pharmaceuticals’ AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
Aridis Pharmaceuticals, Inc. today announced that its AR-301 clinical program has been deemed eligible for consideration under the U.S. Food and Drug Administration’s (FDA) Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).
June 20, 2023
·
6 min read
Policy
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q
Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on May 23, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing Rules due to the Company’s inability to timely file its Form 10-Q for the three months ended March 31, 2023 with the Securities and Exchange Commission.
May 25, 2023
·
5 min read
BioMidwest
Nika Pharmaceuticals, Inc. (NIKA) Presents Its Business Strategy
Nika Pharmaceuticals, Inc. introduces its plans to develop the company into a sustainable business project that will consistently grow, bring good profits and provide dividends to its shareholders.
June 3, 2024
·
5 min read
1 of 69,675
Next